# Caribou Biosciences (CRBU) — News CRBU · NASDAQ · Stock Canonical page: https://www.lighthorse.io/tickers/crbu/news ## Recent headlines - [Caribu Biosciences, Inc.: H.C. Wainwright cuts to neutral from buy](https://www.ainvest.com/news/caribu-biosciences-wainwright-cuts-neutral-buy-2610) — AInvest Wire, Oct 8, 2026 Caribou Biosciences, Inc. (NASDAQ: CRBU) has seen a downgrade in its stock recommendation from H.C. Wainwright, which cut its rating to "neutral" from "buy." This follows a broader shift in analyst sentiment as the company announced plans to evaluate strategic alternatives and discontinue two key… - [Caribou Biosciences, Inc.: RBC cuts to sector perform from outperform; cuts target price to $1 from $10](https://www.ainvest.com/news/caribou-biosciences-rbc-cuts-sector-perform-outperform-cuts-target-price-1-10-2610) — AInvest Wire, Oct 7, 2026 RBC Capital has revised its rating for Caribou Biosciences, Inc. (CRBU), downgrading the stock from "outperform" to "sector perform," while also lowering its target price from $10 to $1. The adjustment reflects a reassessment of the company’s outlook within the biotechnology sector. Investors are… - [Caribu Biosciences, Inc.: Leerink Partners cuts to market perform from outperform; cuts target price to $1 from $4](https://www.ainvest.com/news/caribu-biosciences-leerink-partners-cuts-market-perform-outperform-cuts-target-price-1-4-2610) — AInvest Wire, Oct 7, 2026 Leerink Partners has revised its rating for Caribu Biosciences, Inc. (NASDAQ: CRBU), downgrading the stock from "outperform" to "market perform," while also reducing its price target from $4 to $1. The adjustment reflects a reassessment of the company's near-term prospects and market dynamics. The… - [Caribou Biosciences shares fall 38% to $0.70 after the Bell; announced discontinuing CAR-T cell therapy programs, evaluating strategic alternatives, substantial job cuts](https://www.ainvest.com/news/caribou-biosciences-shares-fall-38-0-70-bell-announced-discontinuing-car-cell-therapy-programs-evaluating-strategic-alternatives-substantial-job-cuts-2610) — AInvest Wire, Oct 6, 2026 Caribou Biosciences (NASDAQ: CRBU) opened 38% lower at $0.70 per share on Monday after the company announced a major restructuring of its operations. The biotech firm disclosed that it is discontinuing its CAR-T cell therapy programs and is evaluating strategic alternatives for its broader cell… - [Trading released/resumed: (CRBU) Reason not available](https://www.ainvest.com/news/trading-released-resumed-crbu-reason-2610) — AInvest Wire, Oct 6, 2026 Trading in Caribou Biosciences, Inc. (CRBU) has resumed following a temporary halt, though the specific reason for the suspension remains undisclosed. The biotechnology company, which operates with a market capitalization of $127.58M as of the latest available data, continues to focus on the… --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).